Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

MONDAY, Feb. 24, 2025 (HealthDay News) -- For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 ...

Mounjaro stimulates the pancreas to release glucagon, which aids in reducing blood sugar levels. To promote appetite suppression, it also delays the emptying of your stomach to make you feel full.

HealthDay News — The glucagon-like peptide-1 receptor agonist ... to receive extended-release exenatide 2 mg by subcutaneous pen injection once per week over 96 weeks or visually identical ...

In a currently running advertisement, the direct-to-consumer telehealth company promotes its ability to prescribe and dispense glucagon-like ... of an injection pen not unlike an existing brand ...

This work presents an important mouse model for a liver-specific depletion of the Survival Motor Neuron (SMN) protein, where the liver retains 30% of functional full-length SMN protein. The authors ...

Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Canada Centre for Neuromuscular Disease, University of Ottawa, Ottawa, Canada Department of Cellular and Molecular Medicine, ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide ... assigned to receive extended-release exenatide 2 mg by subcutaneous pen injection once per week over ...